CURN Intrinsic Valuation and Fundamental Analysis - Kinarus Therapeutics Holding AG

Watchlist Manager

Watchlist

Price: 17.45 CHF 5.44%

Market Cap: CHf92.5m

	Kinarus Therapeutics Holding AG SIX:CURN	CH
X	Xenon Pharmaceuticals Inc F:XP0	CA
	Esprinet SpA MIL:PRT	IT
C	Consolidated Edison Inc XMUN:EDC	US
	Erie Indemnity Co F:EI2	US
T	T S Flour Mill PCL SET:TMILL	TH
G	Gap Inc DUS:GAP	US

Intrinsic Value

Is CURN undervalued or overvalued?

See the intrinsic value estimate for Kinarus Therapeutics Holding AG and find out whether today’s valuation is cheap or expensive by its own historical standards.

Do our valuations actually work? See backtest results .

CURN Intrinsic Value

Unlock

Today vs. history

See how today’s valuation compares with CURN’s past valuations and how the stock performed after similar periods.

See what happened next Free account required

Track Buy Zone

20% below Intrinsic Value

Get notified when the price drops into your buy zone

Current Price CHf17.45

Intrinsic Value Locked

Margin of Safety 20% Locked

Or choose another margin of safety

0% below Intrinsic Value

10% below Intrinsic Value

30% below Intrinsic Value

40% below Intrinsic Value

50% below Intrinsic Value

Custom

Fundamental Analysis

What Kinarus Therapeutics Does

Airlines Industrials

Kinarus Therapeutics Holding AG, a biopharmaceutical company based in Switzerland, emerges at the crossroads of innovative science and unmet medical needs. The company is committed to pioneering novel therapies for chronic disorders, with a strong focus on ophthalmology and fibrotic diseases. At the heart of its operations lies an unwavering dedication to developing pharmaceuticals that can significantly improve patients' lives.

Headquarters: Switzerland CH
IPO date: Oct 18, 1999

Read the full company overview

How Kinarus Therapeutics makes money

The company's financial engine runs on a clinical-stage pipeline that harnesses the potential of drug candidates designed to tackle chronic and progressive conditions. Kinarus generates revenue primarily by advancing these candidates through different phases of clinical trials, aiming for favorable outcomes that will attract partnerships with larger pharmaceutical entities or lead to potential out-licensing agreements. As these collaborations materialize, Kinarus can secure milestone payments, royalties, and licensing fees, which feed back into its research and development endeavors. By striking a balance between scientific acumen and strategic partnerships, Kinarus Therapeutics continues to forge pathways in the biopharmaceutical sector, seeking not only to create financial value but also to deliver transformative solutions for enduring health challenges.

View Company Overview